Hexarelin
Aliases: Examorelin · EP-23905
Last verified: 2026-09-23
The short version
The most potent GHRP for acute GH spikes, but raises cortisol and prolactin and desensitizes quickly. Also has direct cardioprotective effects via CD36 receptors. Key fact: Human data are limited: small trials or case-series reports exist, without large randomized studies. Clinically studied as a GH-deficiency diagnostic and in cardiology; never approved. Status: research chemical. Not approved; WADA-banned (S2).
Identity & type
- Molecular type
- peptide
- Origin
- The most potent GHRP for acute GH spikes, but raises cortisol and prolactin and desensitizes quickly.
Mechanism of action
GHS-R1a agonist (pituitary + hypothalamus) and CD36 agonist in the heart; stimulates GH more strongly than GHRH acutely.
not confirmed in humans
Dosing & routes
Official / clinical context
No approved official document exists for Hexarelin. Any protocols mentioned are to be read as information, not as a recommendation.
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
100–200 mcg SC 1–2× daily; cycles (4–8 weeks) recommended due to desensitization. The strongest GH pulse in the GHRP family, but fast desensitization — the community uses it in short cycles. Marked recovery, pump and sleep are reported; prolactin/cortisol rise with longer use.
Unverified self-reports. Not medical advice. Not endorsement.
Expected effects (community)
The strongest GH pulse in the GHRP family, but fast desensitization — the community uses it in short cycles. Marked recovery, pump and sleep are reported; prolactin/cortisol rise with longer use.
Protocol — official vs community
Official / label
No approved product. Strongest GH release per dose of the GHRP family in study settings.
Duration: Study use only.
Raises prolactin and cortisol at higher doses — the price of its potency.
Community (anecdotal)
100–200 mcg SC up to 3× daily.
- Cycle:
- Short: 4–8 weeks, precisely because of desensitization.
- Break:
- Mandatory 4+ weeks — hexarelin desensitizes GHS-R fastest in class.
Veteran users treat it as a short tool, not a background stack.
Human evidence
Human data are limited: small trials or case-series reports exist, without large randomized studies. Clinically studied as a GH-deficiency diagnostic and in cardiology; never approved.
Preclinical evidence
Clinically studied as a GH-deficiency diagnostic and in cardiology; never approved.
Known risks
- Elevated prolactin and cortisol, water retention, increased hunger (less than GHRP-6), fatigue.characterized
- Unregulated injectable supply — sterility, purity and accurate dose not assuredtheoretical
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- Long-term human safety
- Optimal dose and pharmacokinetics
Frequently asked questions
References
Systematic references are being expanded; verify sources directly before any decision.